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Microorganisms synthesize several compounds with antimicrobial activity in order to 21 
compete or defend themselves against others and ensure their survival. In this line, the cell 22 
wall is a major protective barrier whose integrity is essential for many vital bacterial 23 
processes. Probably for this reason, it represents a ‘hot spot’ as a target for many antibiotics 24 
and antimicrobial peptides such as bacteriocins. Bacteriocins have largely been recognized 25 
by their pore forming ability that collapses the selective permeability of the cytoplasmic 26 
membrane. However, in the last few years, many bacteriocins have been shown to inhibit 27 
cell wall biosynthesis either in a concerted action with pore formation, e.g. nisin, or not. 28 
Examples of cell wall-active bacteriocins are found in both Gram-negative and in Gram-29 
positive bacteria and include a wide diversity of structures such as nisin-like and 30 
mersacidin-like lipid II-binding bacteriocins, two peptide lantibiotics and non-modified 31 
bacteriocins. In this review, we summarize the current knowledge on these antimicrobial 32 
peptides as well as the role, composition and biosynthesis of the bacterial cell wall as their 33 
target. Moreover, even though bacteriocins have been a matter of interest as natural food 34 
antimicrobials, we propose them as suitable tools to provide new means to improve 35 
biotechnologically relevant microorganisms. 36 
 37 
 38 





All living organisms produce some kind of inhibiting substances as part of their defense or 42 
immune system in order to thrive in a competing niche. In particular, microbial antagonism 43 
is well documented and production of antimicrobials includes antibiotics, lytic enzymes, 44 
low-molecular weight metabolites such as organic acids, toxins, and bacteriocins.  45 
Bacteriocins are ribosomally-synthesized antimicrobial peptides or proteins produced by 46 
bacteria with inhibitory (bactericidal or bacteriostatic) activity against species closely 47 
related to the producer (narrow spectrum), or active beyond the genus boundary (broad 48 
spectrum). Although bacteriocin production is not an essential trait in bacteria, it is 49 
evolutionary maintained and widely distributed even though it entails biological costs. 50 
Indeed, it is estimated that around 99 % of bacterial species produce bacteriocins and even 51 
within a species, different bacteriocins can be synthesized [72, 113]. Some bacteriocins 52 
have been shown to be involved in competition among bacterial strains, niche colonization, 53 
and in quorum sensing and communication [32, 34, 51, 118]. 54 
Bacteriocins comprise a very heterogenous group regarding their primary structure and 55 
physico-chemical properties. Likewise, there is a plethora of modes of action targeting 56 
DNA replication, transcription, translation, enzymatic reactions, cell wall biosynthesis or 57 
the cytoplasmic membrane. Disruption of the selective permeability of the membrane by 58 
pore formation is a common inhibitory mechanism for cationic antimicrobial peptides 59 
which are virtually produced by all forms of life [146], including many bacteriocins 60 
synthesized by Gram-positive bacteria (i.e. pore-forming bacteriocins). However, a striking 61 
feature of pore-forming bacteriocins, when compared to their eukaryotic counterparts, is 62 
their high specific activity at the nanomolar range and their relatively limited spectrum of 63 
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activity. This is explained now by the increasing evidence that many of the pore-forming 64 
bacteriocins make target-mediated pores rather than being membrane disruptors. This holds 65 
true for several non-modified bacteriocins that use the membrane-associated component of 66 
the mannose-phosphotransferase system as a specific receptor [40, 72]. Another example is 67 
the use of the cell wall precursor lipid II as a docking molecule for pore formation, 68 
combining inhibition of cell wall biosynthesis with the formation of pores [19, 23]. 69 
Moreover, several non-pore forming bacteriocins targeting the cell wall have been 70 
described able to either hinder cell wall biosynthesis or hydrolyze pre-existing 71 
peptidoglycan.  72 
Based on its essential nature, the biosynthetic pathway of the cell wall has been, and still is, 73 
a validated target in antibiotic development [25, 129]. In view of the need of novel 74 
antimicrobials, cell wall-active bacteriocins are foreseen as a source of novel structures and 75 
activities which may represent new leads for antibiotic development. This review will focus 76 
on cell wall-active bacteriocins synthesized by both Gram-positive and Gram-negative 77 
bacteria. Moreover, examples are given on how these bacteriocins may be used as tools to 78 
improve biotechnological processes by enhancing the performance of the microorganisms 79 
involved. 80 
 81 
Bacteriocin diversity and classification: a constant debate 82 
Bacteriocin production is a widespread trait among bacteria, and some species of Archaea 83 
also produce their own bacteriocin-like compounds called archaeocins [100, 113]. These 84 
are reported to be very resistant to extreme conditions with very promising applications. 85 
5 
 
However, little is known about their mode of action and they will not be covered in this 86 
review.  87 
Among bacteriocins synthesized by Gram-negative bacteria, colicins and microcins, 88 
produced by Escherichia coli and mostly active against Gram-negative microorganisms, 89 
have been extensively studied. Colicins are large proteins (25-80 kDa), usually plasmid-90 
borne that encodes a toxin gene, an immunity gene and, in some cases, a stress-induced 91 
lysis gene. The latter encodes a protein that lyses the producer cell to release the colicin 92 
into the environment. When this gene is absent, the bacteriocin is actively transported 93 
across the membrane. Expression of colicin genes is regulated by the DNA-damage SOS 94 
response, but it can also be influenced by other global regulatory networks [28]. Colicin 95 
production leads to the death of the producing cell and they are lethal for close-related 96 
strains which are recognized by the bacteriocin, being the producer strain immune to them. 97 
All colicins share as to their mode of action common steps that involve recognition of their 98 
cognate receptors in the outer membrane of target cells, translocation across the outer 99 
membrane, and activation of their toxic effect. A great variety of killing mechanisms have 100 
been described such as membrane pore formation (e.g. colicin A), DNA nuclease activity 101 
(colicin E2), and inhibition of the biosynthesis of proteins (colicins E3, E5, D), 102 
peptidoglycan, and the lipopolysaccharide O-antigen (colicin M) [5, 24, 28, 54, 113]. 103 
By contrast, microcins are smaller (<10 kDa), they are not lethal against the producing cell 104 
and their regulation is SOS-independent. Gene clusters are located either in plasmids or in 105 
the chromosome and consist of structural and immunity genes and those coding for 106 
transport or modification enzymes [95]. Two main sub-classes, I and II, have been 107 
established depending on their post-translational modifications, gene cluster organization 108 
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and the sequence of the leader peptide, showing great structural heterogeneity [24, 42, 54]. 109 
Their synthesis is activated under specific stress conditions and, once synthesized, they are 110 
actively transported outside the cell either by microcin-specific or general transporters. 111 
Some microcins recognize specific receptors in the target cell, usually involved in uptaking 112 
essential nutrients. Others are synthesized as harmless peptides which are further processed 113 
and activated within the target cell [43]. Their killing mechanism is not fully understood 114 
but, in some cases, disruption of the cell membrane polarity [79], transcription inhibition by 115 
binding to RNA polymerases [39] or translation inhibition [93] have been documented. 116 
On the other hand, bacteriocins produced by Gram-positive bacteria are usually small, heat-117 
stable cationic peptides with high isoelectric points. They are active preferably against a 118 
wide panel of Gram-positive microorganisms, including food-borne and spoilage bacteria. 119 
This feature has been the main driving force of bacteriocin research, particularly of those 120 
produced by the food-related lactic acid bacteria as for their use as natural preservatives in 121 
food [33, 46]. Bacteriocin gene clusters can be plasmid- or chromosomally-encoded, and 122 
some are localized in transposons, as described for nisin [65]. The gene clusters basically 123 
consist of the structural gene and those involved in immunity. Genes specifying 124 
modification enzymes are also present in some cases. Moreover, Gram-positive 125 
microorganisms have evolved specific regulation mechanisms related to bacteriocin 126 
synthesis and transport [61, 76, 113]. 127 
Owing to the great variety of chemical and structural properties of bacteriocins, several 128 
classification schemes have been proposed based on different criteria such as molecular 129 
weight, producing microorganism, structure or mode of action, although it still remains 130 
controversial and a universal classification is an issue for on-going discussions [36, 73, 97, 131 
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110]. The classification proposed by Heng and Tagg [62] integrates bacteriocins produced 132 
by both Gram-positive and Gram-negative bacteria and establishes four main classes.  133 
Class I or lantibiotics encompasses small (<15 kDa), heat-stable, post-translational-134 
modified peptides containing amino acids such as lanthionine, ß-methyl-lanthionine and 135 
dehydrated amino acids, which form distinctive intramolecular structural rings. Class I is 136 
sub-classified in 3 sub-classes: the linear I-a, represented by cationic and pore-forming 137 
peptides; the globular I-b, non-cationic peptides which inhibit enzymatic reactions; and the 138 
multi-component I-c, composed by two peptides, both needed to be fully active. Class II 139 
bacteriocins are defined as small (<15 kDa), heat-stable, and non-post-translational-140 
modified, usually amphiphilic and/or hydrophobic. They are sub-classified into three sub-141 
classes: Pediocin-like II-a, characterized by a conserved N-terminal sequence YGNGV/L 142 
and a stabilizing disulfide bond, highly active against Listeria and other genera such as 143 
Enterococcus, Lactobacillus, Pediococcus or Clostridium, among others; sub-class II-b 144 
represents a miscellaneous group of linear non-pediocin-like peptides; and sub-class II-c 145 
comprises multi-component bacteriocins. Another group, class III, is composed by large 146 
(>30 kDa) heat-labile proteins, which are sub-divided into sub-class III-a or bacteriolytic 147 
proteins, and sub-class III-b or non-lytic, which are generally active on cytosolic targets. 148 
Finally, class IV includes circular proteins characterized by a head-to-tail covalent bond. 149 
Examples of cell wall-active bacteriocins are shown in Table 1. 150 
 151 
The bacterial cell wall 152 
The cell wall represents the first barrier between the bacterial cells and their environment. It 153 
preserves the integrity of the cell by maintaining a defined and stable cell shape; it is 154 
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needed to counteract the inner osmotic pressure and represents an assembly scaffold for 155 
other surface macrostructures such as polysaccharides, S-layers, flagella and secretion 156 
systems [64, 124]. Moreover, the cell wall is a dynamic structure that participates also in 157 
cell growth and cell division [108, 142]. This structure is, therefore, crucial for survival and 158 
as such it is targeted by several antibiotics, bacteriophages and bacteriocins. 159 
The bacterial cell wall is composed basically by peptidoglycan (PG), anionic polymers, 160 
proteins, and polysaccharides. The PG structure is formed by a network of linear glycan 161 
strands made up of alternating N-acetylglucosamine (NAG) and N-acetylmuramic acid 162 
(NAM) covalently linked by β1-4 glycosidic bonds. Linked to NAM, there is a 163 
pentapeptide chain L-Ala-D-Glu-X-D-Ala-D-Ala, where X represents a diamino acid, 164 
usually a meso-diaminopimelic acid (DAP) in most Gram-negative or L-Lys in Gram-165 
positive bacteria. The glycan strands are further cross-linked via the pentapeptide either 166 
directly or through a short peptide bridge, depending on the species. Since the peptides are 167 
localized helically along the sugar strand, cross-links are made in all directions, forming a 168 
multilayered three-dimensional network [116]. 169 
PG is present in all bacteria, except in Mycoplasmas, Planctomyces and the genera 170 
Rickettsia and Chlamidiae [140]. A scheme of the CW structure of Gram-positive and 171 
Gram-negative bacteria is shown in Fig. 1. In Gram-positive bacteria, the PG represents the 172 
90 % of the total cell wall. Anionic polymers such as teichoic acids (or lipoteichoic acids 173 
when anchored to the cytoplasmic membrane) are also major constituents. Proteins can be 174 
either covalently-linked to PG or associated through cell wall-binding domains. In Gram-175 
negative microorganisms, the PG is a thin layer that accounts only for the 10 % of the CW, 176 
being the external membrane the outermost structure. The lipopolysaccharide (LPS) is the 177 
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major constituent that contributes to the structural integrity of the cell and acts as a 178 
protective barrier.  179 
The biosynthesis of PG is a multistage process beginning in the cytoplasm where the UDP-180 
NAG and UDP-NAM-pentapeptide units are synthesized. Still in the cytoplasm but on the 181 
membrane side, lipid I is synthesized by the addition of the UDP-NAM-pentapeptide unit 182 
to the lipid carrier undecaprenyl-phosphate. Subsequently, UDP-NAG is transferred to lipid 183 
I, yielding lipid II [137]. The PG monomer is translocated through the membrane and, once 184 
in the periplasm, it is polymerized into the growing PG chain by the Penicillin-Binding-185 
Proteins (PBPs), with glycosyltransferase and/or transpeptidase activities [122]. The lipid 186 
carrier is recycled to be used in a new cycle of PG synthesis.  187 
Despite the fact that the basic chemical architecture of the PG is similar in bacteria, no 188 
species keeps its PG in an unmodified state and may vary even within the same species 189 
depending on growth conditions [139]. Modification of the PG may occur along synthesis 190 
and maturation (e.g. degree of cross-linking) but also by the activity of particular enzymes, 191 
very often involved in resistance to antimicrobials. This is the case of PG O-acetylation 192 
accounting for resistance to lysozyme [8, 31, 50] or the presence of D-lactate, D-Ser or Gly 193 
instead of D-Ala in the last position of the pentapeptide in some vancomycin resistant 194 
bacteria [112]. 195 
 196 
Lipid II-binding bacteriocins 197 
Several antibiotics are known to target the different steps of cell wall biosynthesis. 198 
Particularly, the cell wall precursor lipid II is very often targeted and different recognition 199 
domains for several antibiotics have been described [18, 129]. Moreover, it has been 200 
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recently described that some defensins, antimicrobial peptides produced by animals, plants 201 
and fungi, also target lipid II to exert their antibacterial activity [126, 128]. In the case of 202 
bacteriocins, many have been described to bind to lipid II, including pore- and non-pore 203 
forming lantibiotics, non modified bacteriocins, two-peptide bacteriocins and some Gram-204 
negative colicins (Fig. 2). In particular examples, potent inhibitory activities comparable to 205 
leading antibiotics such as vancomycin have been described [69]. 206 
 207 
Nisin and nisin-like bacteriocins 208 
The lantibiotic nisin A is the most studied Gram-positive bacteriocin. It is a 3.3 kDa, 209 
elongated, amphiphilic and positively-charged peptide with a wide spectrum of activity, 210 
inhibiting several Gram-positive and also some Gram-negative bacteria, provided that the 211 
external membrane is disrupted [133]. Several natural nisin variants, produced by 212 
Lactococcus lactis (nisin A, Z, F and Q) and by Streptococcus uberis (nisin U), have been 213 
isolated. Early work on the mode of action of nisin already suggested that cell wall 214 
biosynthesis was inhibited [111] and, later on, it was experimentally confirmed that nisin 215 
makes use of lipid II as a docking molecule for pore formation [19, 23]. Lipid II is an 216 
integral part of the pore which is made up of 8 molecules of nisin and 4 of lipid II [59]. The 217 
combination of both, inhibition of cell wall biosynthesis and pore formation, is the basis of 218 
the potent activity of nisin. Binding to lipid II also implies that the cell wall precursor is 219 
delocalized from the sites where is needed for cell wall biosynthesis, interfering with cell 220 
growth and cell division [60, 68]. Moreover, binding to lipid II is also needed for effective 221 
membrane disruption in germinated spores to inhibit spore outgrowth from several 222 
pathogenic Gram-positive bacteria [56, 90]. Nisin has also been reported to activate cell 223 
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wall hydrolytic enzymes, particularly in staphylococci at the septum level, by displacing 224 
them from the teichoic and lipoteichoic acids [12, 13].  225 
The N-terminus of nisin, specifically rings A and B, forms an essential binding cage which 226 
interacts with the pyrophosphate moiety of lipid II via hydrogen bonds [67] and the C-227 
terminus is essential for pore formation [145]. Their contribution to bacterial killing has 228 
been assessed by using mutated nisin versions [145]. Interestingly, specific mutations on 229 
the hinge region resulted in nisin variants with enhanced activity [45]. 230 
The nisin-like lipid II-binding structural motif is present in many pore-forming lantibiotics 231 
such as gallidermin and epidermin [15], mutacin 1140 [132], subtilin [105] and bovicin 232 
HC5 [104], whose interaction with lipid II has been experimentally demonstrated. Of note, 233 
the pore forming ability of these nisin-like lipid II-binding peptides seems to be strongly 234 
dependent on membrane thickness and composition and determines the inhibitory spectra 235 
of these lantibiotics. Thereby, in order to evaluate the contribution of pore formation to the 236 
mode of action of these and other bacteriocions, special care must be taken when choosing 237 
a particular susceptible strain [138]. 238 
 239 
Mersacidin and mersacidin-like lantibiotics 240 
Mersacidin is a small 1.8 kDa globular uncharged lantibiotic produced by Bacillus HIL Y-241 
84,54728 [30]. It is active against a variety of Gram-positive bacteria and, remarkably, 242 
against methicillin-resistant Staphylococcus aureus (MRSA) with comparatively higher 243 
activity than vancomycin in animal models [30, 74, 98]. Mersacidin is not a pore-forming 244 
bacteriocin. Instead, it strongly inhibits the transglycosilation step during cell wall 245 
biosynthesis by binding to lipid II without affecting the biosynthesis of DNA, RNA or 246 
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proteins [21, 22]. The structure of the complex mersacidin-lipid II has not been solved. 247 
However, NMR analyses revealed that mersacidin possesses a dynamic conformation able 248 
to suffer structural changes depending on the environmental conditions, thus modulating 249 
the distribution of the charged residues, which affects the effective interaction with lipid II 250 
[66]. Moreover, mersacidin activity is enhanced by calcium ions in vivo, promoting its 251 
interaction with the negatively charged surface of the cytoplasmic membrane [16]. 252 
Mersacidin and related lantibiotics are characterized by the presence of an interwined 253 
tioether bridge within the conserved TxS/TxE/DC motif, being the glutamate residue 254 
essential for the inhibitory activity, as shown by site-directed mutagenesis [134]. This 255 
pattern is conserved in other lantibiotics indicating a putative inhibitory activity of these 256 
bacteriocins based on lipid II-binding [14].  257 
Among mersacidin-like lantibiotics, inhibition of cell wall biosynthesis has been 258 
demonstrated for plantaricin C and nukacin ISK-1 [70, 143]. Moreover, the lantibiotic 259 
planosporicin was discovered during a screening for inhibitors of peptidoglycan inhibitors 260 
[29]. There are several lantibiotics whose structure resembles that of plantaricin C and 261 
nukacin ISK-1 (i.e. the lacticin 481 group). They all have their particular inhibitory spectra 262 
and their activity could rely also on lipid II-binding and pore formation [7, 14, 41]. 263 
Plantaricin C is a 3.5 kDa bacteriocin, synthesized by Lactobacillus plantarum LL441, 264 
which displays inhibitory activity against a wide range of Gram-positive bacteria, including 265 
food-borne pathogens, such as Staphylococcus, Streptococcus, Clostridium or Bacillus [52]. 266 
It shares structural features with nisin and mersacidin; it has a highly positively-charged N-267 
terminus, which may facilitate the interaction with the negatively charged cytoplasmic 268 
membrane, and a ring and compact conformation in the C-terminus, resembling the 269 
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mersacidin lipid II-binding motif [136]. Accordingly, plantaricin C is able to form pores in 270 
model membranes and intact cells of particular bacterial species but it is also a potent 271 
inhibitor of cell wall biosynthesis forming a tighter complex with lipid II when compared to 272 
mersacidin [53, 143]. 273 
Nukacin ISK-1 is a 2.9 kDa lantibiotic produced by Staphylococcus warneri ISK-1 with a 274 
N-terminal linear domain and a globular C-terminus, essential for the antimicrobial activity, 275 
which holds the mersacidin-like lipid II-binding motif TxS/TxD/EC [71, 121]. Nukacin 276 
ISK-1 is bacteriostatic and unable to form pores. Instead, it binds to lipidII leading to the 277 
accumulation of cell wall precursors inside the cell. Treated cells show a reduced thickness 278 
of the cell wall and incomplete septa [2]. Immunity has been associated with the 279 
cooperative role of the ABC transporter NukFEG and the lantibiotic-binding immunity 280 
protein NukH, which may block the bacteriocin before reaching its target [101]. 281 
 282 
Two-peptide lantibiotics 283 
A growing class of lipid II-binding molecules is constituted by two-peptide lantibiotics or 284 
class Ic according to the Heng and Tagg’s classification [62]. In these systems, two pre-285 
peptides are ribosomally-synthesized as inactive forms (LanA1 and LanA2) which are later 286 
enzimatically-modified into their mature forms, the α-peptide carrying a mersacidin-like 287 
lipid II domain and an elongate positively-charged ß-peptide involved in pore formation. 288 
Both peptides are enconded by their corresponding structural genes, act synergistically 289 
usually in a 1:1 ratio, and are required for full activity. This distribution of specialized 290 
killing mechanisms in two peptides has been described for lacticin 3147 [144] and 291 
haloduracin [102] and may hold true for other closely related two-peptide lantibiotics [99]. 292 
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Lacticin 3147 is synthesized by L. lactis ssp. lactis DPC3147 and it is highly active against 293 
Gram-positive bacteria, including food-borne pathogens such as Listeria monocytogenes 294 
and Bacillus cereus or relevant pathogens such as MRSA [91, 119, 120]. Lacticin 3147 295 
structure was resolved by Martin et al [83] and it is composed by LtnA1 (3.3 kDa), the 296 
globular-type lantibiotic with a mersacidin-like lipid II-binding motif, and LtnA2 (2.8 kDa), 297 
a positively-charged elongated-type lantibiotic. Both peptides are needed for high 298 
inhibitory activity at nanomolar concentration [96, 144]. LtnA1 has been shown to be a 299 
strong inhibitor of cell wall biosynthesis in in vitro assays. The interaction with lipid II 300 
appears to stabilize LtnA1 promoting its interaction with LtnA2, capable of pore formation 301 
[91, 144]. Potassium release assays showed that LtnA1 should be present before the final 302 
action of LtnA2, demonstrating that LtnA1 and LtnA2 act in a sequential manner in a 1:1 303 
ratio, an event which has been frequently found for other two-peptide bacteriocins [96 and 304 
references therein]. Mutagenesis assays showed that the rings of LtnA1 involved in lipid II-305 
binding, the glutamate residue in this region, as well as the rings in LtnA2 involved in the 306 
interaction of the two peptides, are essential for activity [35]. In addition to this, the 307 
presence of calcium ions, or in general a positively-charged environment, was proved to 308 
enhance the antimicrobial activity of lacticin 3147 as LtnA1 binds to whole cells only when 309 
it is surrounded by positive charges, either calcium or the positively-charged partner LtnA2 310 
[16]. It is worth-noting that the inhibitory activity is also strain-dependent [96]. 311 
Haloduracin is produced by the alkaliphilic Bacillus halodurans C-125 and have inhibitory 312 
activity against several Gram-positive bacteria and also inhibits spore outgrowth of Bacillus 313 
anthracis [80], being its effectiveness strain-dependent [103]. It is composed of two 314 
lantibiotic-type peptides, Halα (2.8 kDa) and Halβ (2.3 kDa) [92], which act synergistically 315 
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at a nanomolar concentration. Halα contains several overlapping rings and the lipid II-316 
binding motif present in mersacidin, actagardine and LtnA of lacticin 3147, while Halβ 317 
shows a more elongated structure. Halα binds to lipid II and inhibits transglycosilation by 318 
PBP1 during PG biosynthesis. This complex promotes binding of Halβ that forms pores in 319 
the membrane [102]. This sequential mechanism of action, suggested to occur in a 320 
lipidII:Halα:Halβ (1:2:2) ratio, is similar to that of lacticin 3147 despite having significant 321 
structural differences [102, 103]. 322 
 323 
Lactococcin 972 324 
Lactococcin 972 (Lcn972) is a 7.5 kDa, cationic and highly active bacteriocin synthesized 325 
by Lactococcus lactis IPLA972. So far, it is the first non-lantibiotic that does not target the 326 
cytoplasmic membrane, i.e. it does not make pores [86]. Rather, it inhibits PG biosynthesis 327 
by binding specifically to lipid II. Lcn972 activity was antagonized in vivo by lipid II, and 328 
not by other cell wall precursors. Lcn972 also co-precipitated with micelles containing lipid 329 
II, and interfered in vitro with the enzymatic reactions of PBP2 (polymerization of PG) and 330 
FemX, both enzymes that use lipid II as a substrate [84]. In contrast to other lipid II-331 
binding bacteriocins, Lcn972 shows two particular features: first, it seems to block the 332 
incorporation of cell wall precursors at the septum; and second, it possesses a narrow 333 
activity spectrum, being active exclusively against lactococci under active division [85]. 334 
The existence of a putative co-target has been proposed to explain this targeted mode of 335 
action.  336 
Another striking feature is that Lcn972 is easily inactivated by heat, anticipating a complex 337 
structure-function relationship. Lcn972 was claimed to be a homodimer based on the results 338 
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of in-gel bioassays in which the inhibitory activity appeared to be linked to a 15 kDa band, 339 
instead of the expected 7.5 kDa [86]. However, recent experimental data revealed that this 340 
aberrant migration occurred only in the presence of glycerol that stabilizes the folded form 341 
of Lcn972 and preliminary NMR data further discard the presence of such a homodimer 342 
[Turner D., personal communication]. 343 
The lack of homology between Lcn972 and other lipid II-binding peptides suggests that 344 
Lcn972 carries a novel lipid II-binding motif. Interestingly, there are more than 100 hits in 345 
the public databases that are related to Lcn972, building the protein family Pfam09683. 346 
 347 
Colicin M 348 
Within Gram-negative bacteriocins, colicin M, a 29.5 kDa protein synthesized by E. coli, is 349 
a unique colicin that interferes with the biosynthesis of PG and the O-antigen of the LPS in 350 
susceptible E. coli strains [57, 58, 123]. Colicin M is imported in susceptible cells by 351 
recognizing the ferrichrome receptor FhuA, and subsequently energy-dependent 352 
translocated into the periplasm to exert its antimicrobial activity [17, 130]. Its narrow 353 
activity spectrum is due to the species-specific condition of the receptors and the 354 
translocation mechanisms involved. It has a phosphoesterase activity which degrades lipid 355 
II, specifically cleaving the phosphodiester bond between the lipid moiety and the 356 
pyrophosphoril group [44, 57], in a magnessium-dependent manner [4]. Consequently, the 357 
lipid carrier C-55 cannot be recycled in new PG synthesis rounds nor in the synthesis of the 358 
O-antigen. Interestingly, Patin et al [106] have demonstrated that colicin M can hydrolyze 359 
in vitro and in vivo any lipid II molecule regardless the composition of the peptide side 360 
chain, thus representing a good candidate to study cell wall degradation in bacteria.  361 
17 
 
The structure of colicin M revealed a complex folded conformation challenging the 362 
identification of the typical colicin domains [147]. However, the high identity observed in 363 
the C-terminus of colicin M and other orthologs in several species of Burkholderia, 364 
Pectobacterium, and virulent Pseudomonas, supports the notion that the catalytic domain 365 
resides in this region, while the N-terminus and the central region are likely involved in 366 
target receptor recognition and translocation, respectively [5, 109, 147].  367 
 368 
Cell wall-degrading bacteriocins 369 
Several large and heat-sensitive proteins synthesized by bacteria that hydrolyze the cell 370 
wall have been described. They are comprised into class IIIa (so-called bacteriolysins), 371 
although their classification as bacteriocins is controversial [36, 62]. Bacteriolysins are 372 
usually organized in modules bearing catalytic activities and target recognition domains, 373 
resembling those present in bacteriophage endolysins [63], and streptococcal fratricins [9]. 374 
Immunity proteins are encoded in the vicinity of the structural genes and they often encode 375 
FemABX-like proteins, peptidyl tranferases that catalyze the incorporation of amino acid(s) 376 
into the interchain peptide bridge of the PG [11, 48]. Examples of class IIIa bacteriolysins 377 
are listed in Table 1 and some examples are given below.  378 
 379 
Lysostaphin 380 
Lysostaphin may be the most studied bacteriolytic bacteriocin with regard to clinical 381 
applications. It is a 27 kDa metallo-enzyme firstly identified in Staphylococcus simulans 382 
[125] and highly specific against Staphylococcus aureus [3, 55]. Its mature form displays 383 
an N-terminal domain responsible for the catalytic activity, and a C-terminal involved in 384 
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binding to the target PG [3]. Lysostaphin is a glycylglycine endopeptidase targeting the 385 
pentaglycine cross-bridge of the PG in many staphylococci [55], cleaving specifically 386 
between the third and the fourth Gly residues [127]. Producer strains do not have specific 387 
immunity genes; instead, they are resistant due to the plasmid-encoded gene lif, involved in 388 
the addition of serine residues to the pentaglycine bridge that prevents hydrolysis by 389 
lysostaphin [38, 135]. Several authors have proposed lysostaphin as an effective therapeutic 390 




Zoozin A is a 30 kDa endopeptidase synthesized by Streptococcus equi subsp. 395 
zooepidemicus 4881 that hydrolyzes the bond between the terminal D-alanine of the peptide 396 
side chain and the L-alanine of the cross bridge in the PG of sensitive streptococci [49]. It 397 
carries two functional domains: the catalytic N-terminus, showing high similarity to other 398 
PG endopeptidases such as lysostaphin, and the C-terminal domain involved in PG 399 
recognition and binding [1]. Immunity relies on zif, involved in the addition of alanine 400 
residues to the cross bridge, making it longer and more resistant to hydrolysis. Zif shows 401 
high similarity with FemABX-like proteins [48, 117]. 402 
 403 
Millericin B 404 
Millericin B is a 28 kDa PG hydrolase synthesized by Streptococcus milleri NMSCC 061 405 
with inhibitory activity against a wide range of Gram-positive bacteria. Its endopeptidase 406 
activity cleaves both at the peptide side chain and the cross bridge [10]. Beukes and 407 
19 
 
Hastings [11] have identified three genes putatively involved in immunity and export. milF 408 
and tRNAleu incorporate leucine residues into the cross bridge that hinder hydrolysis. milT 409 
is homologous to ABC transporters and is likely involved in millericin export.  410 
 411 
Pesticin 412 
Within Gram-negatives, PG hydrolytic enzymes are also found. For example, pesticin is a 413 
39.9 kDa bacteriocin synthesized by Yersinia pestis which kills other Yersinia species and 414 
some E. coli strains [28]. The genetic organization and its three-domain structural 415 
architecture resemble that of colicins featuring an N-terminal translocation domain, a 416 
central receptor binding domain, and the C-terminal activity domain. The activity domain 417 
has a similar folding to lysozyme-related proteins such as the archetypal phage T4 lysin 418 
[107]. Although they differ in sequence, both T4 lysozyme and pesticin share the same 419 
enzymatic activity, cleaving the β1-4 glycosidic bond between NAM and NAG in the PG 420 
chain [141]. Like colicin M, pesticin’s receptor is the outer membrane iron-syderophore 421 
transporter FyuA which also plays a role as virulent factor of many pathogens. Immunity to 422 
pesticin relies on Pim, a protein which specifically recognizes a sequence located in the 423 
catalytic domain. 424 
The modular organization of pesticin allowed designing a hybrid bacteriocin composed by 425 
the FyuA-receptor domain and a foreign phage-related muramidase domain, not recognized 426 
by the immunity protein Pim. This hybrid bacteriocin is able to penetrate across the outer 427 




Cell wall-active bacteriocins as biotechnological tools 430 
Bacteriocins have mainly been considered as food biopreservatives, particularly those 431 
produced by lactic acid bacteria (LAB). In fact, more than 700 patents related to LAB 432 
bacteriocins have been registered and more than 400 are linked to the improvement of food 433 
quality, probiotics for animal feed, and mastitis treatment [46, 94]. The potential of LAB 434 
bacteriocins in food biopreservation relies basically on the traditional role of these bacteria 435 
as starters in food fermentations and their GRAS (Generally Regarded As Safe) status. 436 
Moreover, the bacteriocins they produce do not have a toxic effect on eukaryotic cells [46, 437 
82] and they have a wider spectrum of activity compared to those produced by Gram-438 
negative bacteria, impairing the development of food-borne pathogens. Accordingly, 439 
several LAB bacteriocins are commercialized in several countries as food biopreservatives. 440 
Their application as biopreservatives in food has been extensively reviewed elsewhere [46, 441 
47, 94, 97].  442 
From a clinical point of view, the development of pathogens such as vancomycin-resistant 443 
enterococci (VRE) and MRSA is of particular concern to animal and public health agencies 444 
worldwide. In this line, bacteriocins such as nisin, lacticin 3147, mersacidin or lysostaphin 445 
have also been considered as an alternative to traditional antibiotics [6, 37, 74, 75, 131].  446 
Besides the applications of bacteriocins based on their antibiotic activities, cell wall-active 447 
bacteriocins may be also very useful to study cell wall biology and, particularly, the 448 
response to cell envelope stress in relevant microorganisms. As outlined below, this 449 
approach has been exemplified by the role of the cell-wall active bacteriocin Lcn972 in 450 
understanding the molecular mechanisms that govern the response of the industrially 451 
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relevant L. lactis to cell wall damaging. The generated knowledge has provided a basis for 452 
improving L. lactis performance in food fermentations (Fig. 3). 453 
L. lactis is the main component of the mesophilic starter cultures used in cheese 454 
manufacturing and robust strains are continuously demanded to improve the yield of 455 
industrial fermentations and guarantee the optimal characteristics of the final fermented 456 
product [20]. In the dairy environment, L. lactis must tolerate diverse stress conditions 457 
either during starter manufacture or along the fermentation process. Thus, the knowledge 458 
on how L. lactis monitors cell wall integrity and develops appropriate responses is, without 459 
a doubt, relevant to optimize its performance and robustness. In this context, the 460 
transcriptional response of L. lactis to Lcn972 helped to identify CesSR as the main two 461 
component system (TCS) that orchestrates the primary line of defense to cell wall damage 462 
in this microorganism [87]. Several genes in L. lactis were identified as members of the 463 
CesR regulon and among them, llmg0169 and the operon llmg2164-2163, encoding a 464 
putative membrane protein and a Psp-like protein, respectively, were highly induced. These 465 
genes could be further correlated to a higher survival of L. lactis under technological stress 466 
such as low pH, heat, or NaCl, among others, and have been proposed as biomarkers for 467 
strain robustness [114] (Fig. 3).  468 
The charaterization of resistant mutants to cell wall-active bacteriocins of industrially 469 
relevant microorganisms may also help to select more robust strains and reveal interesting 470 
mechanisms by which they become better adapted to their industrial use. For instance, a 471 
recent work has shown that L. lactis is able to shorten the peptide chain of its muropeptides 472 
to counteract the activity of Lcn972. Remarkably these mutants were also insensitive to 473 
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other dairy preservatives such as lysozyme and nisin, and to some bacteriophages which are 474 
a major threat in dairy fermentations [115]. 475 
There are as well examples of biotechnological applications derived from the current 476 
knowledge on cell wall-active bacteriocins. CesSR and its orthologues in other Gram-477 
positives such as LiaSR in B. subtilis and VraSR in S. aureus were shown to be specifically 478 
induced by lipid II-binders such as nisin, bacitracin and vancomycin [78, 87, 88]. This 479 
feature has been further exploited to develop HTS (High-Throughput Screening) reporter 480 
systems to identify cell wall active compounds and monitor the stress response they trigger. 481 
These methods were designed with the aim to be easy-handling, quick and applicable to 482 
high amount of samples. A reporter B. subtilis strain was created by fusing the promoter of 483 
the TCS LiaSR to the lacZ gene, thus expressing beta-galactosidase as response to 484 
antibiotics interfering with the lipid II cycle [89]. Qualitative assays were performed with 485 
agar-diffusion-tests and quantification was possible in liquid cultures in microtiter plates, 486 
thus, enabling to screen and identify lipid II-interfering compounds [26]. Similarly, the 487 
promoter of llmg0169, the most up-regulated gene after CesSR activation in L. lactis, was 488 
fused to the gene encoding the green fluorescense protein (GFP) and a microtiter 489 
fluorescence-based assay was developed to monitor cell envelope response in L. lactis 490 
under specific conditions [27]. 491 
 492 
In view of these highlighted reports, cell wall-active bacteriocins are envisaged, not only as 493 
effective antimicrobials, but also as tools to get a deeper knowledge on the genetic and 494 
physiological consequences of cell wall damage in bacteria. Understanding bacterial 495 
23 
 
regulatory mechanisms involved in stress responses may ultimately lead to a rational 496 
selection of industrially relevant microorganisms for specific applications. 497 
 498 
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Fig.1 Scheme of the structure of the cell wall of Gram-positive (left) and Gram-negative 920 
(right) bacteria. CM: cytoplasmic membrane. PG: peptidoglycan. OM: outer membrane. 921 
NAG: N-acetylglucosamine. NAM: N-acetylmuramic acid. LPS: lipopolysaccharide 922 
 923 
Fig.2 Mode of action of some cell wall-active bacteriocins. Square: N-acetylglucosamine. 924 
Triangle: N-acetylmuramic acid. CM: cytoplasmic membrane. PG: peptidoglycan. Within 925 
the PG, β1-4 glycosidic bonds (horizontal lines) and cross-bridges (vertical lines). Boxes: 926 
detailed muropeptide composition of streptococcal (left) and staphylococcal (right) 927 
peptidoglycan 928 
 929 
Fig.3 Overview of the role of lactococcin 972 (Lcn972) as a tool to study cell wall damage 930 
and resistance mechanisms in the industrial strain Lactococcus lactis, with the aim of 931 
improving performance in dairy fermentations. HK: histidin kinase. RR: response regulator. 932 
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product DESIGN OF ROBUST STARTERSIMPROVEMENT
Table 1 Examples of cell wall-active bacteriocins 
 
a According to Heng and Tagg [62] 
b CW: cell wall; PG: peptidoglycan 
Bacteriocin Classa  Singular featuresb  Reference 
Nisin Ia Linear lantibiotic Combines lipid II-mediated pore 





Mersacidin Ib Globular lantibiotic Inhibits transglycosilation during 
CW biosynthesis 
[22] 
Plantaricin C Ia/Ib Globular pore-forming 
lantibiotic 
Shares structural/functional 




Nukacin ISK-1 Ia/Ib Globular non-pore-
forming lantibiotic 
Binds to lipid II accumulating 
CW precursors 
[2] 
Lacticin 3147 Ic Multi-component lantibiotic Combines pore formation and 




Haloduracin Ic Multi-component lantibiotic Combines pore formation and 




Lactococcin 972 IIIa Heat-sensitive  Binds to lipid II blocking the 
incorporation of CW precursors at 
the septum  
 
[84] 
Colicin M IIIb Non-lytic large protein Hydrolyses lipid II [106] 
Lysostaphin IIIa Bacteriolytic large protein Glycilglycine endopeptidase at 




Zoozin A IIIa Bacteriolytic large protein Endopeptidase at the peptide side 
chain  
[48] 
Millericin B IIIa Bacteriolytic large protein Endopeptidase at the peptide side 
chain and cross-bridge 
[10] 
Pesticin IIIa Bacteriolytic large protein Hydrolyses glycan chains [107] 
